BIG problems require BIG solutions
A Global Crisis We Can’t Ignore
A Global Crisis We Can’t Ignore
Microbes may be small, but they create BIG problems when they develop resistance to antibiotics. For over a century, antibiotics have been the backbone of modern medicine—treating infections, enabling life-saving surgeries and protecting the most vulnerable. But now, the rise and spread of drug resistance is threatening to reverse all this.
Drug-resistant infections are already one of the world’s biggest killers, associated with nearly 5 million deaths a year. Without urgent action, this crisis will escalate, putting everyone, everywhere in danger.
We’re at a critical tipping point
In 2024, global leaders made a BIG commitment to tackle antimicrobial resistance (AMR). Now we urgently need to turn those words into action because drug resistance has reached a critical tipping point.
Without a radical shift in the global response, we should expect a sharp rise in the number of AMR deaths, increasing by 70% by 2050. To avoid this, significant investment is needed in developing new antibiotics to replace those lost to resistance, and in improving access to essential antibiotics across the globe.
Flipping the model to develop the right antibiotics
At GARDP, we are making both these goals possible by flipping the traditional antibiotics research and development (R&D) model on its head. By putting people’s health at the centre of antibiotic development we can make a BIG difference.
Our mission is to ensure that the right antibiotics are developed to meet the greatest public health needs. We do this by shifting the priority towards high-burden countries and by focusing on antibiotics that target multidrug-resistant infections that pose the greatest threat to people.
Ensuring access where it’s needed most
Developing the right antibiotics is only part of the solution. Ensuring that people everywhere have access to life-saving treatments is just as critical. Too often, new and essential antibiotics remain out of reach for the communities that need them most.
That is why GARDP factors equitable access into every stage of the drug development process, from scientific discovery and R&D, right through to the manufacturing, registration and last mile delivery of antibiotics. Because improving access could have a BIG impact, preventing more than 50 million deaths by 2050.
Changing the way antibiotics are developed and accessed
Changing the way antibiotics are developed and accessed
GARDP is taking bold steps to change the future of antibiotics, but we can’t do it alone. Together, we can stop the surge in drug-resistant infections and save millions of lives.
Be part of the change.
#ThisIsBig
